Nat Commun:癌症转移不用怕!新研究切断癌细胞的“粮草”,将它们活活饿死!

2017-10-18 佚名 medicalxpress

如果癌症不发生转移,那么治愈的可能性非常大,但更大的挑战在于治疗癌症转移,或从原发肿瘤扩散到病人身体的其他部位。虽然免疫疗法可有效治疗转移性疾病,但适用的病人却非常有限。

如果癌症不发生转移,那么治愈的可能性非常大,但更大的挑战在于治疗癌症转移,或从原发肿瘤扩散到病人身体的其他部位。虽然免疫疗法可有效治疗转移性疾病,但适用的病人却非常有限。

埃弗拉德古德曼依兰大学生命科学学院的研究人员们确定了一种酶,这种酶支持转移性细胞的生存和传播,因此,研究人员合成一种化合物,目标酶,杀死转移性癌细胞。他们的研究刚刚发表在《自然通讯》杂志上。

癌细胞离开原发肿瘤会拥有更大的生存工具,即使是在非常恶劣的条件,如缺乏基本的营养物质如葡萄糖。转移性细胞可通过重组他们的能源发电系统防止这种代谢缺陷。在此次研究中,研究小组发现一种FerT酶的存在,当他们在实验室中有针对性的攻击这种酶的时候,恶性肿瘤细胞无法产生能量,并且走向死亡。团队开始在身体的其他部位寻找酶,他们发现它只存在于一个特定的细胞中,那就是精子细胞。

“精子细胞是唯一可以在体外发挥功能的细胞,就像转移性细胞一样,精子细胞也是独一无二的,他们还可以在非常严酷的条件下产生能量。一旦进入女性产道,即使没有血液供应,他们也可以生产大量的能量。我们发现转移性癌细胞,并确定精子细胞的特定蛋白质,并且了解如何模仿制作它,利用它。”

研究人员使用先进的化学和机械方法,开发了一种人工合成的化合物,可以口服或注射给患者,这种化合物成为E260,它们首先进入转移性细胞,然后进入线粒体,也就是癌细胞的发电站,它们结合酶FerT,扭曲其活动,非常值得注意的是,它们不仅抑制其活性,还可以使整个线粒体电站完全崩溃。

原始出处:

Yoav Elkis, Moshe Cohen, Etai Yaffe, et.al. A novel Fer/FerT targeting compound selectively evokes metabolic stress and necrotic death in malignant cells. Nature Communications 8, Article number: 940 (2017)

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2087164, encodeId=67f2208e16483, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Fri Sep 28 07:28:00 CST 2018, time=2018-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=260653, encodeId=474126065355, content=学习了谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Sun Nov 12 00:51:12 CST 2017, time=2017-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=259358, encodeId=aff725935808, content=学习了.获益匪浅!感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/07/17/0ed05bbc4eb124766d2a39104932ec4e.jpg, createdBy=5afd2091871, createdName=情途末路, createdTime=Tue Nov 07 07:00:57 CST 2017, time=2017-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1882543, encodeId=a1b41882543d0, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Thu Jul 26 23:28:00 CST 2018, time=2018-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252376, encodeId=a7e212523e6d8, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Fri Oct 20 04:28:00 CST 2017, time=2017-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379099, encodeId=a08913e909961, content=<a href='/topic/show?id=e185e14882c' target=_blank style='color:#2F92EE;'>#癌症转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71488, encryptionId=e185e14882c, topicName=癌症转移)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=50ba440, createdName=xirongguo, createdTime=Fri Oct 20 04:28:00 CST 2017, time=2017-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=254061, encodeId=c9bb25406127, content=绝佳好办法.癌症治疗进步了., beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Wed Oct 18 16:21:10 CST 2017, time=2017-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=254030, encodeId=a9ad25403025, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Wed Oct 18 13:49:12 CST 2017, time=2017-10-18, status=1, ipAttribution=)]
    2018-09-28 liuli5079
  2. [GetPortalCommentsPageByObjectIdResponse(id=2087164, encodeId=67f2208e16483, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Fri Sep 28 07:28:00 CST 2018, time=2018-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=260653, encodeId=474126065355, content=学习了谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Sun Nov 12 00:51:12 CST 2017, time=2017-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=259358, encodeId=aff725935808, content=学习了.获益匪浅!感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/07/17/0ed05bbc4eb124766d2a39104932ec4e.jpg, createdBy=5afd2091871, createdName=情途末路, createdTime=Tue Nov 07 07:00:57 CST 2017, time=2017-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1882543, encodeId=a1b41882543d0, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Thu Jul 26 23:28:00 CST 2018, time=2018-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252376, encodeId=a7e212523e6d8, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Fri Oct 20 04:28:00 CST 2017, time=2017-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379099, encodeId=a08913e909961, content=<a href='/topic/show?id=e185e14882c' target=_blank style='color:#2F92EE;'>#癌症转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71488, encryptionId=e185e14882c, topicName=癌症转移)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=50ba440, createdName=xirongguo, createdTime=Fri Oct 20 04:28:00 CST 2017, time=2017-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=254061, encodeId=c9bb25406127, content=绝佳好办法.癌症治疗进步了., beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Wed Oct 18 16:21:10 CST 2017, time=2017-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=254030, encodeId=a9ad25403025, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Wed Oct 18 13:49:12 CST 2017, time=2017-10-18, status=1, ipAttribution=)]
    2017-11-12 1e145228m78(暂无匿称)

    学习了谢谢作者分享!

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2087164, encodeId=67f2208e16483, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Fri Sep 28 07:28:00 CST 2018, time=2018-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=260653, encodeId=474126065355, content=学习了谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Sun Nov 12 00:51:12 CST 2017, time=2017-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=259358, encodeId=aff725935808, content=学习了.获益匪浅!感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/07/17/0ed05bbc4eb124766d2a39104932ec4e.jpg, createdBy=5afd2091871, createdName=情途末路, createdTime=Tue Nov 07 07:00:57 CST 2017, time=2017-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1882543, encodeId=a1b41882543d0, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Thu Jul 26 23:28:00 CST 2018, time=2018-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252376, encodeId=a7e212523e6d8, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Fri Oct 20 04:28:00 CST 2017, time=2017-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379099, encodeId=a08913e909961, content=<a href='/topic/show?id=e185e14882c' target=_blank style='color:#2F92EE;'>#癌症转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71488, encryptionId=e185e14882c, topicName=癌症转移)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=50ba440, createdName=xirongguo, createdTime=Fri Oct 20 04:28:00 CST 2017, time=2017-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=254061, encodeId=c9bb25406127, content=绝佳好办法.癌症治疗进步了., beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Wed Oct 18 16:21:10 CST 2017, time=2017-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=254030, encodeId=a9ad25403025, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Wed Oct 18 13:49:12 CST 2017, time=2017-10-18, status=1, ipAttribution=)]
    2017-11-07 情途末路

    学习了.获益匪浅!感谢分享

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2087164, encodeId=67f2208e16483, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Fri Sep 28 07:28:00 CST 2018, time=2018-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=260653, encodeId=474126065355, content=学习了谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Sun Nov 12 00:51:12 CST 2017, time=2017-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=259358, encodeId=aff725935808, content=学习了.获益匪浅!感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/07/17/0ed05bbc4eb124766d2a39104932ec4e.jpg, createdBy=5afd2091871, createdName=情途末路, createdTime=Tue Nov 07 07:00:57 CST 2017, time=2017-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1882543, encodeId=a1b41882543d0, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Thu Jul 26 23:28:00 CST 2018, time=2018-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252376, encodeId=a7e212523e6d8, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Fri Oct 20 04:28:00 CST 2017, time=2017-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379099, encodeId=a08913e909961, content=<a href='/topic/show?id=e185e14882c' target=_blank style='color:#2F92EE;'>#癌症转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71488, encryptionId=e185e14882c, topicName=癌症转移)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=50ba440, createdName=xirongguo, createdTime=Fri Oct 20 04:28:00 CST 2017, time=2017-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=254061, encodeId=c9bb25406127, content=绝佳好办法.癌症治疗进步了., beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Wed Oct 18 16:21:10 CST 2017, time=2017-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=254030, encodeId=a9ad25403025, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Wed Oct 18 13:49:12 CST 2017, time=2017-10-18, status=1, ipAttribution=)]
    2018-07-26 liye789132251
  5. [GetPortalCommentsPageByObjectIdResponse(id=2087164, encodeId=67f2208e16483, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Fri Sep 28 07:28:00 CST 2018, time=2018-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=260653, encodeId=474126065355, content=学习了谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Sun Nov 12 00:51:12 CST 2017, time=2017-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=259358, encodeId=aff725935808, content=学习了.获益匪浅!感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/07/17/0ed05bbc4eb124766d2a39104932ec4e.jpg, createdBy=5afd2091871, createdName=情途末路, createdTime=Tue Nov 07 07:00:57 CST 2017, time=2017-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1882543, encodeId=a1b41882543d0, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Thu Jul 26 23:28:00 CST 2018, time=2018-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252376, encodeId=a7e212523e6d8, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Fri Oct 20 04:28:00 CST 2017, time=2017-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379099, encodeId=a08913e909961, content=<a href='/topic/show?id=e185e14882c' target=_blank style='color:#2F92EE;'>#癌症转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71488, encryptionId=e185e14882c, topicName=癌症转移)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=50ba440, createdName=xirongguo, createdTime=Fri Oct 20 04:28:00 CST 2017, time=2017-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=254061, encodeId=c9bb25406127, content=绝佳好办法.癌症治疗进步了., beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Wed Oct 18 16:21:10 CST 2017, time=2017-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=254030, encodeId=a9ad25403025, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Wed Oct 18 13:49:12 CST 2017, time=2017-10-18, status=1, ipAttribution=)]
    2017-10-20 yxch36
  6. [GetPortalCommentsPageByObjectIdResponse(id=2087164, encodeId=67f2208e16483, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Fri Sep 28 07:28:00 CST 2018, time=2018-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=260653, encodeId=474126065355, content=学习了谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Sun Nov 12 00:51:12 CST 2017, time=2017-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=259358, encodeId=aff725935808, content=学习了.获益匪浅!感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/07/17/0ed05bbc4eb124766d2a39104932ec4e.jpg, createdBy=5afd2091871, createdName=情途末路, createdTime=Tue Nov 07 07:00:57 CST 2017, time=2017-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1882543, encodeId=a1b41882543d0, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Thu Jul 26 23:28:00 CST 2018, time=2018-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252376, encodeId=a7e212523e6d8, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Fri Oct 20 04:28:00 CST 2017, time=2017-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379099, encodeId=a08913e909961, content=<a href='/topic/show?id=e185e14882c' target=_blank style='color:#2F92EE;'>#癌症转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71488, encryptionId=e185e14882c, topicName=癌症转移)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=50ba440, createdName=xirongguo, createdTime=Fri Oct 20 04:28:00 CST 2017, time=2017-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=254061, encodeId=c9bb25406127, content=绝佳好办法.癌症治疗进步了., beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Wed Oct 18 16:21:10 CST 2017, time=2017-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=254030, encodeId=a9ad25403025, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Wed Oct 18 13:49:12 CST 2017, time=2017-10-18, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=2087164, encodeId=67f2208e16483, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Fri Sep 28 07:28:00 CST 2018, time=2018-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=260653, encodeId=474126065355, content=学习了谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Sun Nov 12 00:51:12 CST 2017, time=2017-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=259358, encodeId=aff725935808, content=学习了.获益匪浅!感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/07/17/0ed05bbc4eb124766d2a39104932ec4e.jpg, createdBy=5afd2091871, createdName=情途末路, createdTime=Tue Nov 07 07:00:57 CST 2017, time=2017-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1882543, encodeId=a1b41882543d0, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Thu Jul 26 23:28:00 CST 2018, time=2018-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252376, encodeId=a7e212523e6d8, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Fri Oct 20 04:28:00 CST 2017, time=2017-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379099, encodeId=a08913e909961, content=<a href='/topic/show?id=e185e14882c' target=_blank style='color:#2F92EE;'>#癌症转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71488, encryptionId=e185e14882c, topicName=癌症转移)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=50ba440, createdName=xirongguo, createdTime=Fri Oct 20 04:28:00 CST 2017, time=2017-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=254061, encodeId=c9bb25406127, content=绝佳好办法.癌症治疗进步了., beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Wed Oct 18 16:21:10 CST 2017, time=2017-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=254030, encodeId=a9ad25403025, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Wed Oct 18 13:49:12 CST 2017, time=2017-10-18, status=1, ipAttribution=)]
    2017-10-18 1e0f8808m18(暂无匿称)

    绝佳好办法.癌症治疗进步了.

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=2087164, encodeId=67f2208e16483, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Fri Sep 28 07:28:00 CST 2018, time=2018-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=260653, encodeId=474126065355, content=学习了谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Sun Nov 12 00:51:12 CST 2017, time=2017-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=259358, encodeId=aff725935808, content=学习了.获益匪浅!感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/07/17/0ed05bbc4eb124766d2a39104932ec4e.jpg, createdBy=5afd2091871, createdName=情途末路, createdTime=Tue Nov 07 07:00:57 CST 2017, time=2017-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1882543, encodeId=a1b41882543d0, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Thu Jul 26 23:28:00 CST 2018, time=2018-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252376, encodeId=a7e212523e6d8, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Fri Oct 20 04:28:00 CST 2017, time=2017-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379099, encodeId=a08913e909961, content=<a href='/topic/show?id=e185e14882c' target=_blank style='color:#2F92EE;'>#癌症转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71488, encryptionId=e185e14882c, topicName=癌症转移)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=50ba440, createdName=xirongguo, createdTime=Fri Oct 20 04:28:00 CST 2017, time=2017-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=254061, encodeId=c9bb25406127, content=绝佳好办法.癌症治疗进步了., beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Wed Oct 18 16:21:10 CST 2017, time=2017-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=254030, encodeId=a9ad25403025, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Wed Oct 18 13:49:12 CST 2017, time=2017-10-18, status=1, ipAttribution=)]
    2017-10-18 131****1460

    学习了受益匪浅

    0

相关资讯

Nat Med:为什么癌症无法治愈?研究给出新的解释!

靶向抗癌疗法西妥昔单抗和帕尼单抗是治疗晚期结肠直肠癌的主要手段,是美国癌症相关死亡的第二大原因。然而,许多患者具有遗传突变的肿瘤,使得它们对这些抗表皮生长因子受体(EGFR)单克隆抗体具有抗性,或者癌症在治疗期间产生抗性。寻求了解内在和获得性抗性机制的研究人员把研究重点集中在基因突变上,例如在致癌基因KRAS中激活突变。

我国自主研发治疗非小细胞肺癌药获批临床试验

近期我国抗肿瘤药物研究取得新突破。记者17日从中科院上海药物研究所获悉,具有我国自主知识产权的抗肿瘤1类新药ASK120067已获得国家食品药品监督管理总局颁发的临床试验批件,获批进入临床研究。

Nat Commun:糖如何加剧癌症?Nature子刊为你揭示

众所周知,癌细胞比普通细胞摄入更高水平的葡萄糖并经历更多糖酵解途径,但这背后的机制一直尚未明确。近日,发表于Nature Communications上的一项研究揭示了些许答案。

Sci Rep:人参皂苷Rh2抗癌新靶点发现

吉林大学分子酶学工程教育部重点实验室金英花教授课题组通过噬菌体展示技术对人源肝癌细胞cDNA文库进行系统筛选,获得47种人参皂苷Rh2的作用靶点,这将为人参防癌抗癌作用研究提供新思路。

Cell Rep:癌症新突破,全新角度,消除治疗副作用!

弗朗西斯·克里克研究所的研究人员已经发现一种新药,可以用于治疗肠癌,相比较传统治疗,这种新药的毒性更低。

Cancer Res:研究确定影响癌症发展的重要标志物,把复发扼杀在摇篮里!

西奈山医学院的科学家们和科罗拉多州立大学弗雷德哈钦森癌症中心的研究人员们共同进行的关于胶质母细胞瘤的研究有了进一步的结果,研究人员确定了反应病人预后以及应对特定疗法的生物标记物。研究结果出版在近日出版的《癌症研究》中。